Pactster: Improving adherence to specialist exercise for better physical and emotional health in adults with Cystic Fibrosis

“Pactster是一个以社区为基础的锻炼平台，为有特定健康状况的人服务。我们提供针对具体情况的锻炼视频和社区支持，包括在线团体锻炼，以鼓励人们更多地锻炼身体和情绪健康。作为最初的目标市场，我们选择了囊性纤维化（CF），这是一种影响英国10，000多人的疾病，每年的费用至少为24，000英镑/患者。我们之所以选择CF，是因为定期锻炼对疾病的管理有着深远的影响，而且由于担心交叉感染，他们面临着无法亲自见面的独特障碍（这意味着团体锻炼课程是不可能的）。在向CF市场推出我们的产品后的12个月里，我们得到了患者（已获得英国市场的3%），他们的护理人员，临床医生和英国及其他地区更广泛社区的非常令人鼓舞的反应。这是一个很好的开始，但我们面临的主要挑战之一是提高锻炼的坚持性和激励用户做更多的锻炼。为了加快我们克服这一挑战的步伐，并开始显着改善CF患者的生活，我们提出了一个为期12个月的项目，研究，设计，实施，测试和评估三种技术干预措施，主要目的是增加CF患者的运动量。凭借技术，健康和营销专家团队，特别是在囊性纤维化领域，并得到顾问和战略合作伙伴的支持，他们将在项目期间提供支持，我们完全有能力进行成功和有意义的可行性研究，以了解如何利用技术创新来提高运动依从性。该项目的结果有可能对CF患者的生活产生强大的影响，从而降低NHS治疗该疾病的成本。此外，随着我们在英国和全球卫生部门推出Pactster，患有其他健康状况（乳腺癌和前列腺癌，艾滋病和糖尿病）的人将继续感受到这种影响。"

"Pactster is a community-based exercise platform for people with specific health conditions. We offer condition-specific exercise videos and community support, including online group exercise, to encourage people to exercise more for better physical and emotional health. As an initial target market we have chosen cystic fibrosis (CF), a disease affecting over 10,000 people in the UK, with annual costs of at least £24,000/patient. We chose CF due to profound impact regular exercise can have on the management of the disease and the unique barrier they face in not being able to meet in person for fear of cross-infection (meaning group exercise classes are out of the question). In the 12 months since launching our product to the CF market we have had extremely encouraging response from people with the disease (have acquired 3% of the UK market), their carers, clinicians and the wider community both in the UK and beyond. It's a great start, however one of the key challenges we face is improving exercise adherence and motivating users to do more exercise. To speed up the pace at which we can overcome this challenge and start significantly improving the lives of people with CF we propose a 12 month project to research, design, implement, test and evaluate three technology interventions with the primary aim of increasing the amount of exercise people with CF are doing. With a team of technology, health and marketing experts, specifically in the field of cystic fibrosis, and backed by advisors and strategic partnerships who will provide support during the project, we are perfectly positioned to conduct a successful and meaningful feasibility study into how technological innovations can be used to increase exercise adherence. The outcome of this project has the potential to have a powerful impact on the lives of people with CF and as a result reduce costs to the NHS in treating the disease. Moreover, the impact will continue to be felt by people with other health conditions (breast and prostate cancer, HIV and diabetes to name but a few) as we roll out Pactster out across the health sector in the UK and worldwide."